04/12/2017 12:01:03

Arix Bioscience leads $30 million financing for Atox Bio

Arix Bioscience leads $30 million financing for Atox Bio

Funding to

advance Reltecimod into a Phase 2 clinical study for acute kidney injury, building upon Atox Bio's on-going Phase 3 clinical development in necrotising soft tissue infections

Arix achieves target of 12 Group Businesses by the end of 2017, successfully building a balanced group with multiple, potentially significant milestones over the next 12 months

LONDON, 4 December 2017: Arix Bioscience plc (LSE: ARIX) ("Arix Bioscience" or "Arix"), a global healthcare and life science company supporting medical innovation, today announces that it has led an oversubscribed $30 million Series F financing round for Atox Bio. Atox Bio is a late stage clinical biotechnology company developing novel immune modulators for critically ill patients with severe infections including necrotising soft tissue infections (NSTI) and acute kidney injury (AKI).

The $30 million fundraising led by Arix Bioscience included new investors Adams Street Partners, Asahi Kasei Corporation and additional undisclosed investors, alongside existing investors SR One, OrbiMed, Lundbeckfonden Ventures, Becker and Integra Holdings.

Arix Bioscience is investing $8 million for an equity stake in Atox Bio. As part of the financing, Arix Bioscience's Jonathan Tobin will join Atox Bio's Board of Directors.

Atox Bio's lead therapeutic candidate, Reltecimod, is a novel peptide that modulates the body's immune response, lowering the risk of potential morbidities and mortality. Reltecimod received Orphan Drug status from the FDA and EMA as well as Fast Track designation. Atox Bio is conducting a Phase 3 clinical study of Reltecimod for patients with NSTIs, and will start a Phase 2 clinical study for AKIs in 2018.

Joe Anderson, Chief Executive Officer of Arix Bioscience, commented: "We are pleased to have led this successful financing round for Atox Bio, which is developing therapies for severe, potentially life-threatening conditions in the critical care setting where no other therapies exist. Necrotising soft tissue infections and acute kidney injury are major unmet medical needs, and we look forward to supporting the company to develop treatments that would be potentially life-changing for patients.

"With this high quality deal, Arix Bioscience has met the target we set out at our IPO to have 12 Arix Group Businesses by the end of 2017. Over the coming months, our Group Businesses will reach multiple, potentially significant milestones which, if successful, will support the further development of breakthrough innovation for patients and value for shareholders."

Dan Teleman, Chief Executive Officer of Atox Bio, commented: "We are excited to welcome such high quality investors into the existing strong syndicate. The success of this round reflects the significant achievements we have made to date in the development of Reltecimod and recognition of the critical unmet medical need for treatments for NSTI and AKI."

For more information, please contact:

Arix Bioscience plc

Joe Anderson, CEO

+44 (0)20 7290 1052

Matthew Cole, Communications Director

+44 (0)20 7290 1065

Consilium Strategic Communications

Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan

+44 (0)20 3709 5700

arix@consilium-comms.com

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

For further information, please visit www.arixbioscience.com

About Atox Bio

Atox Bio is a late stage clinical biotechnology company with operations in the US and Israel that develops novel immune modulators for critically ill patients with severe infections. Atox Bio has an ongoing contract with the Biomedical Advanced Research and Development Authority (BARDA) supporting the development of Reltecimod in NSTI. Atox Bio was established by Prof. Raymond Kaempfer and Dr. Gila Arad from the Hebrew University of Jerusalem and Yissum.

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
13 Dec
FING-B
Hvem tør efterhånden investere på børsen, med dette ufatteligt ødelæggende shorting og naked-short v..
30
10 Dec
VWS
Der er simpelhen så meget støj i marked omkring Vestas. Prøv at vurdere disse få tal, og din beslutn..
26
14 Dec
VELO
Faldt lige over denne artikel, som er frigivet 20/11 2017.... Asertaa-studiet med dens konklusioner ..
20
10 Dec
VELO
  @djks Tak for dine altid velovervejede indlæg, som er af stor betydning for debatten, idet man som..
18
12 Dec
BAVA
Prøver du at dække dig ind under Bavarian for at undgå at vi snakker om dine enorme tab i Matas og R..
17
10 Dec
NOVO-B
En julehilsen fra alpehue, og  et "Olympic" tillykke til Novo, dens aktionærer og verdens diabetespa..
17
13 Dec
GEN
Han har ingen model. Det er noget han altid skriver. Det er som i SKAT - der mangler ikke folk i Ska..
15
14 Dec
VWS
Citat: »Vores ordreindgang voksede 50 pct. i det seneste kvartal. Der er intet galt med vores salg, ..
14
12 Dec
GEN
Minder lige om denne fra d. 21.11.2017:http://medwatch.dk/Medicinal___Biotek/article10047753.ece   "..
14
09 Dec
VWS
Lad mig prøve vs. Vestas at tage "prispres" fra en anden side, for der er også prispres i USA !!   M..
14

Alliance Trust PLC : Transaction in Own Shares

15/12/2017 07:00:16
15 December 2017  Alliance Trust PLC TRANSACTION IN OWN SHARES  The Board of Alliance Trust PLC ("the Company") announces that on 14 December 2017 the Company purchased for cancellation 184,000 ordinary shares of 2.5p each at a price of 737.0383p per share.  Therefore, the total number of voting rights in the Company is now 347,592,156.    The above figure (347,592,156) may be used by sha..

Form 8.3 - Tesco PLC

14/12/2017 11:47:54
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Jupiter Asset Management (b) Owner or controlle..

Dimensional Fund Advisors Ltd. : Form 8.3 - Tesco Plc - Ordinary shares

14/12/2017 10:47:13
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Dimensional Fund Advisors Ltd. ("Dimensional"), in its capacity ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Voip-Pal.com, Inc. Discusses the Global Potential of its RBR Parent Patent
2
Make Christmas Personal with New Celebrity Video Ecards from American Greetings
3
Impac Mortgage Holdings, Inc. Announces Hire of Rian Furey to lead its Consumer Direct Retail Channel
4
Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae
5
Mesoblast grants TiGenix an exclusive global patent license to use adipose-derived mesenchymal stem cells in the local treatment of fistulae

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
15 December 2017 08:19:22
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171124.1 - EUROWEB4 - 2017-12-15 09:19:22 - 2017-12-15 08:19:22 - 1000 - Website: OKAY